Supriya Lifescience Limited (NSE:SUPRIYA)

India flag India · Delayed Price · Currency is INR
698.25
-6.45 (-0.92%)
Apr 29, 2026, 3:29 PM IST
1.27%
Market Cap 56.72B
Revenue (ttm) 7.35B
Net Income (ttm) 1.85B
Shares Out 80.48M
EPS (ttm) 23.04
PE Ratio 30.59
Forward PE 23.98
Dividend 1.00 (0.14%)
Ex-Dividend Date Sep 4, 2025
Volume 122,395
Average Volume 214,388
Open 704.70
Previous Close 704.70
Day's Range 695.00 - 707.80
52-Week Range 545.50 - 832.40
Beta 0.28
RSI 64.74
Earnings Date May 26, 2026

About Supriya Lifescience

Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti–hypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1987
Employees 515
Stock Exchange National Stock Exchange of India
Ticker Symbol SUPRIYA
Full Company Profile

Financial Performance

In fiscal year 2025, Supriya Lifescience's revenue was 6.96 billion, an increase of 22.12% compared to the previous year's 5.70 billion. Earnings were 1.88 billion, an increase of 57.80%.

Financial Statements

News

There is no news available yet.